SLU-PP-332

Key Benefits#

• Significant enhancement of aerobic endurance capacity
• Increases mitochondrial density and oxidative metabolism in muscle
• Promotes beneficial shift toward oxidative muscle fiber phenotype
• Improves cardiac efficiency and cardiovascular fitness markers
• Potential for obesity, metabolic syndrome, and heart failure treatment
• Exercise mimetic for populations unable to exercise (disability, frailty, disease)

Mechanism of Action#

SLU-PP-332 binds and activates ERRalpha and ERRdelta nuclear receptors, which regulate the transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. Activated ERRa/d upregulate PGC-1alpha co-activator activity, increase mitochondrial density in skeletal muscle, shift fiber type toward oxidative slow-twitch fibers, and enhance cardiac efficiency. In rats, 4-week treatment increased treadmill endurance by up to 70% compared to untrained controls.

Dosing Protocols#

Side Effects#

• Limited human data; all studies are preclinical (rodent)
• Unknown cardiovascular effects with long-term or high-dose use in humans
• Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
• Off-target effects not fully characterized

Contraindications#

No human use data; research compound onlyHormone-sensitive cancers (ERR pathway caution)Pregnancy: contraindicatedChildren and adolescents: unknown developmental effects

Storage#

Store at -20 degrees C as lyophilized powder or in organic solvent (DMSO). Reconstituted aqueous solutions are unstable; prepare fresh. Protect from light.

1. 1.
   Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes

   Avliyakulov NK, Sobolevsky T, Ahrens E · Drug testing and analysis · 2026PubMed Verified

2. 2.
   In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential

   Möller T, Krug O, Thevis M · Rapid communications in mass spectrometry : RCM · 2026PubMed Verified

3. 3.
   An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity

   Billon C, Appourchaux K, Côté I, Burris TP · The Journal of pharmacology and experimental therapeutics · 2026PubMed Verified

4. 4.
   Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study

   Bonanni R, Falvino A, Matticari A, Rinaldi AM, D'Arcangelo G, Cifelli P et al. · Frontiers in physiology · 2025PubMed Verified

5. 5.
   Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function

   Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A et al. · Circulation · 2024PubMed Verified

6. 6.
   A Synthetic ERR Agonist Alleviates Metabolic Syndrome

   Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B et al. · The Journal of pharmacology and experimental therapeutics · 2024PubMed Verified

7. 7.
   Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney

   Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA et al. · The American journal of pathology · 2023PubMed Verified

8. 8.
   Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity

   Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L et al. · ACS chemical biology · 2023PubMed Verified